Xlue Raises $35M Seed to Build an AI 'World Model' for Human Health

Carnegie Mellon spinout Xlue raised a $35 million seed led by Conviction to build an AI model that forecasts patient health trajectories instead of predicting text.

Key Takeaways

  • Xlue raised $35 million in seed funding led by Conviction, announced November 18, 2026, with no valuation disclosed.
  • The company is a 2025 Carnegie Mellon University spinout founded by Chenyan Xiong, Ophir Frieder and Hao-Ren Yao.
  • Xlue's 'human health world model' predicts how patient health states change over time to forecast disease risk and simulate clinical trials.
  • In an October third-party evaluation, Xlue's model led on 14 of 16 disease risk prediction tasks at about $0.04 per 1,000 predictions.
  • Total funding raised to date is $35 million, Xlue's first disclosed institutional round.

Xlue Raises $35M Seed to Build an AI 'World Model' for Human Health

Xlue, a health AI startup spun out of Carnegie Mellon University, has raised $35 million in seed funding led by Conviction, the firm founded by Sarah Guo. The company announced the round on November 18, 2026, alongside the public launch of its technology: a foundation model trained on patient health states and treatment actions rather than on text tokens. No valuation was disclosed.

The round positions Xlue among a small cluster of startups betting that large language model techniques can be repurposed to forecast how a person's health changes over time, rather than to generate text or images.

What Xlue builds and how it has performed so far

Xlue calls its core product a "human health world model." Instead of predicting the next word in a sentence, the system is trained to predict how a patient's clinical state evolves in response to treatment decisions, with the goal of forecasting disease risk and simulating clinical trial outcomes before they are run in the real world.

The company is already running prospective disease risk studies with health systems and working with pharmaceutical companies interested in simulating treatment responses. In an independent evaluation conducted in October by the firm Protege across 2,500 patients, Xlue's model flagged the most future disease cases on 14 of 16 risk prediction tasks, at a cost of roughly $0.04 per 1,000 predictions, according to figures cited in coverage of the launch.

Who is behind the company and the money

Xlue was founded in 2025 by Chenyan Xiong, a Carnegie Mellon professor who spent five years building language models at Microsoft Research, alongside Ophir Frieder and Hao-Ren Yao. Xiong serves as chief executive. The $35 million seed is the company's first disclosed institutional funding, bringing total raised to date to $35 million.

Where Xlue sits against rivals

Xlue enters a field where Oracle has been building clinical trial AI agents into its health data infrastructure, and Knit Health has developed a competing product called Med-BEAM aimed at similar disease-forecasting tasks. Xlue's pitch is narrower and more technical: rather than wrapping an existing large language model around clinical data, it trains a model explicitly on sequences of health states and interventions, a structure closer to the "world models" being developed for robotics and autonomous systems than to a conventional medical chatbot.

That framing matters for how investors are valuing health AI right now. Seed and early-stage health AI rounds have increasingly rewarded startups that can show a measurable prediction advantage over incumbents, rather than general-purpose AI wrappers.

What to watch next

Xlue has not disclosed the scope or outcomes of its prospective health-system studies, nor named its pharmaceutical partners. The company also has not said how it plans to generate revenue — whether through direct health system licensing, pharmaceutical trial simulation contracts, or both. Investors and competitors will be watching for published results from its ongoing studies and whether it can convert pilot deployments into paying enterprise contracts over the next year.

Category: Funding & Investments

Tags: Conviction world model Carnegie Mellon Xlue health AI disease prediction

Related Articles

Frequently Asked Questions

How much funding did Xlue raise?

Xlue raised $35 million in seed funding, announced November 18, 2026.

Who led Xlue's funding round?

Conviction, the AI-focused venture firm founded by Sarah Guo, led the round.

What does Xlue's technology do?

It is a 'health world model' trained on patient health states and treatments to predict disease risk and simulate clinical trial outcomes.

Who founded Xlue?

Carnegie Mellon professor Chenyan Xiong founded Xlue in 2025 with Ophir Frieder and Hao-Ren Yao.

How much has Xlue raised in total?

$35 million to date, all from this seed round.